联环药业
(600513)
| 流通市值：61.92亿 | | | 总市值：61.92亿 |
| 流通股本：2.85亿 | | | 总股本：2.85亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,285,342,346.98 | 627,705,511.57 | 2,160,457,160.63 | 1,644,578,576.25 |
| 营业收入 | 1,285,342,346.98 | 627,705,511.57 | 2,160,457,160.63 | 1,644,578,576.25 |
| 二、营业总成本 | 1,230,280,455.15 | 587,869,188.52 | 2,050,251,134.72 | 1,516,612,393.88 |
| 营业成本 | 786,613,734.42 | 367,224,522.89 | 1,093,743,600.55 | 824,022,908.65 |
| 税金及附加 | 10,210,703.62 | 4,707,131.63 | 19,736,310.55 | 14,807,669.41 |
| 销售费用 | 263,149,785.33 | 145,209,909.62 | 613,910,294.64 | 459,172,224.37 |
| 管理费用 | 86,783,433.5 | 41,387,718.67 | 144,812,545.38 | 106,058,391.31 |
| 研发费用 | 68,423,933.06 | 22,273,387.47 | 154,589,086.68 | 94,317,179.81 |
| 财务费用 | 15,098,865.22 | 7,066,518.24 | 23,459,296.92 | 18,234,020.33 |
| 其中:利息费用 | 15,570,894.61 | 7,202,674.9 | 24,951,127.75 | 18,910,310.58 |
| 其中:利息收入 | 351,738.21 | 108,149.22 | 679,073.4 | 582,086.05 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -2,292,190.27 | -1,523,863.03 | -10,586,429.4 | -5,619,978.64 |
| 资产处置收益 | - | - | 35,029,139.47 | -700 |
| 资产减值损失(新) | -927,206.48 | -453,642.02 | -5,211,934.12 | -387,662.65 |
| 信用减值损失(新) | -2,626,861.6 | 1,149,040.1 | -8,145,010.15 | -4,976,129.62 |
| 其他收益 | 4,031,900.88 | 2,269,307.26 | 9,727,230.56 | 5,501,078.08 |
| 四、营业利润 | 53,247,534.36 | 41,277,165.36 | 131,019,022.27 | 122,482,789.54 |
| 加:营业外收入 | 320,753.13 | 261,820.05 | 27,508.81 | 26,096.34 |
| 减:营业外支出 | 61,074,105.39 | 80,316.43 | 618,747.83 | 529,389.23 |
| 五、利润总额 | -7,505,817.9 | 41,458,668.98 | 130,427,783.25 | 121,979,496.65 |
| 减:所得税费用 | 24,851,779.14 | 14,064,770.91 | 24,013,037.91 | 14,440,492.06 |
| 六、净利润 | -32,357,597.04 | 27,393,898.07 | 106,414,745.34 | 107,539,004.59 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -32,357,597.04 | 27,393,898.07 | 106,414,745.34 | 107,539,004.59 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -40,028,355.46 | 23,059,579.59 | 84,159,987.05 | 92,699,157.34 |
| 少数股东损益 | 7,670,758.42 | 4,334,318.48 | 22,254,758.29 | 14,839,847.25 |
| 扣除非经常损益后的净利润 | 19,509,365.93 | 22,150,470.79 | 49,867,999.96 | 90,437,843.43 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.14 | 0.08 | 0.29 | 0.32 |
| (二)稀释每股收益 | -0.14 | 0.08 | 0.29 | 0.32 |
| 八、其他综合收益 | -96,708.4 | -93,937.21 | 78,920.88 | -73,049.96 |
| 归属于母公司股东的其他综合收益 | -96,708.4 | -93,937.21 | 78,920.88 | -73,049.96 |
| 九、综合收益总额 | -32,454,305.44 | 27,299,960.86 | 106,493,666.22 | 107,465,954.63 |
| 归属于母公司股东的综合收益总额 | -40,125,063.86 | 22,965,642.38 | 84,238,907.93 | 92,626,107.38 |
| 归属于少数股东的综合收益总额 | 7,670,758.42 | 4,334,318.48 | 22,254,758.29 | 14,839,847.25 |
| 公告日期 | 2025-08-27 | 2025-04-30 | 2025-04-18 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |